Blood Test for Breast Cancer Associated Auto Antibodies
Recruitment status was: Recruiting
Intend of use: A blood test for Cancer Associated Auto Antibodies (CAAA) aimed for better diagnostic management of suspected subjects with breast pathology
Study Description: Blood is collected form patients and serum is tested for the presence of CAAA on experimental test kit.
Objectives: To assess the effectiveness of the CAAA test.
Patient Population: The study population will include any women with suspected breast mass detected by any conventional method, scheduled for biopsy, which will result with a pathological verification of the suspected mass.
Target Population: The target population will be any women with suspected breast mass detected by any conventional method, that today, is scheduled for biopsy.
Structure: Subjects that will be enrolled for the study will be checked for the presence of CAAAb, and the results of the CAAAb test will be compared to the pathology submitted by the physicians in the participating centers.
Sample Size: Total of 1000 samples, of which 620 samples will ensure at least 124 true positive breast cancer subjects verified by biopsy, and 124 true negative breast cancer subjects verified by biopsy. Additional 400 samples will be used for calibrations and training sets.(Multi center study, statistical rationale provided below).
Primary Effectiveness Variables: The effectiveness of the test will be defined by the specificity of the test conditionally that the sensitivity is not lower than a pre-defined level of 95%.
Endpoint: The endpoint of this study is to show that the effectiveness is higher than 50%.
Study Sponsor: Eventus Diagnostics Ltd.
Clinical Monitor: For each site a dedicated CRO will be appointed to monitor the clinical trials. All data will be stored in a protected internet-based database, and any changes of the data will be traced and recorded.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Blood Test for Breast Cancer Associated Auto Antibodies|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01343849
|Contact: Tanir Allweis, MDemail@example.com|
|Contact: Nadia Sinaifirstname.lastname@example.org|
|Ora, Jerusalem, Israel, 90880|
|Contact: Galit Yahalom, Ph.D. 972-546-922422 email@example.com|
|Contact: Nadia Sinai 972-2-6507939 firstname.lastname@example.org|
|Principal Investigator: Tanir Allweis, MD|
|Principal Investigator:||Tanir Allweis, MD||Kaplan Medical Center|